A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Docetaxel; Prednisone

Criteria

Inclusion Criteria:

• You are at least 18 years old.

• You live close enough to the doctor's office to attend all of your required visits.

• You have not been treated with chemotherapy for your prostate cancer.

• Your organs must be functioning properly.

Exclusion Criteria:

• You are unable to swallow pills.

• You have another serious illness besides your prostate cancer.

• You have taken another experimental drug within the last 30 days.

• You have a serious heart condition.

• You are receiving another anti-cancer therapy.